4.8 Article

Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1

期刊

CELL METABOLISM
卷 31, 期 5, 页码 987-+

出版社

CELL PRESS
DOI: 10.1016/j.cmet.2020.04.007

关键词

-

资金

  1. Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG19991, IG15748, IG19928]
  2. European Research Council (ERC) [FP7-282280]
  3. European Union FP7 CIG [PCIG13GA-2013-618697]
  4. Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) [FIRB RBAP11Z3YA_005, PRIN 2017BF3PXZ, PRIN 2017FS5SHL]
  5. University of Padua STARS Consolidator FIRMESs
  6. ERC [H2020-725004]
  7. CERCA Programme/Generalitat de Catalunya
  8. European Foundation for the Study of Diabetes (EFSD)/Lilly Research grant
  9. MINECO (Spain) - European Regional Developmental Fund (ERDF), a Way to Build Europe [SAF2017-89116R-P]
  10. FP7-Cofund DTI-IMPORT
  11. AIRC Fellowship
  12. Fonds Leon Fredericq (University of Liege)
  13. Foundation Umberto Veronesi fellowship

向作者/读者索取更多资源

While endothelial cell (EC) function is influenced by mitochondrialmetabolism, the role ofmitochondrial dynamics in angiogenesis, the formation of new blood vessels from existing vasculature, is unknown. Here we show that the inner mitochondrial membrane mitochondrial fusion protein optic atrophy 1 (OPA1) is required for angiogenesis. In response to angiogenic stimuli, OPA1 levels rapidly increase to limit nuclear factor kappa-light-chain-enhancer of activated B cell (NFkB) signaling, ultimately allowing angiogenic genes expression and angiogenesis. Endothelial Opa1 is indeed required in an NFkB-dependent pathway essential for developmental and tumor angiogenesis, impacting tumor growth and metastatization. A firstin-class small molecule-specific OPA1 inhibitor confirms that EC Opa1 can be pharmacologically targeted to curtail tumor growth. Our data identify Opa1 as a crucial component of physiological and tumor angiogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据